| Not Yet Recruiting | Electroacupuncture as a Treatment for Refractory Overactive Bladder NCT07124390 | Chelsea and Westminster NHS Foundation Trust | N/A |
| Recruiting | Safety and Performance of UCon Patch Electrode NCT06754189 | InnoCon Medical | N/A |
| Recruiting | APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women NCT06797245 | Medstar Health Research Institute | N/A |
| Recruiting | Examination of the Effect of Nocturia on Pelvic Floor Symptoms, Sleep Parameters and Quality of Life in Women NCT06866834 | Gulhane School of Medicine | — |
| Not Yet Recruiting | Transcutaneous Tibial Nerve Stimulation for Overactive Bladder Syndrome and Associated Gait Changes in Post-me NCT06617676 | Louisiana State University Health Sciences Center Shreveport | N/A |
| Withdrawn | Pathophysiologic Study to Understand and Possibly Treat Nocturia NCT05298384 | NYU Langone Health | N/A |
| Completed | Efficacy of Vaginal 17β-Estradiol on the Urinary Storage Symptoms in Postmenopausal Women NCT06508944 | Mahidol University | Phase 4 |
| Recruiting | Safety and Performance of UCon Bar Electrode for the Treatment of Overactive Bladder (OAB) and Bowel Dysfuncti NCT06091566 | InnoCon Medical | N/A |
| Completed | Mandibular Advancement Device and Changes in Nocturia NCT05562388 | Fernanda Yanez Regonesi | N/A |
| Recruiting | Multi-center Trial to Improve Nocturia and Sleep in Older Adults NCT06110091 | Atlanta VA Medical Center | N/A |
| Recruiting | UCon Treatment of Overactive Bladder (OAB) in Males NCT05874375 | InnoCon Medical | N/A |
| Recruiting | Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women NCT05604222 | Shachi Tyagi | Phase 4 |
| Completed | A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia NCT05597020 | Idorsia Pharmaceuticals Ltd. | Phase 4 |
| Completed | Sleep, Hypertension, and Nocturia: a Multicomponent Approach for Comorbid Illnesses NCT05419830 | University of Pittsburgh | N/A |
| Completed | TUCSON Study: Tackling Underlying Causes of Sleep Related Nocturia Nocturia NCT05404828 | University Hospital, Ghent | — |
| Completed | Safety and Performance of UCon for the Treatment of the Symptoms of Overactive Bladder (OAB) / Bowel Dysfuncti NCT05368246 | InnoCon Medical | N/A |
| Recruiting | Lymphoedema and Nocturia/Nocturnal Polyuria After Pelvic LND for Urogenital Cancer NCT05300308 | Universitaire Ziekenhuizen KU Leuven | — |
| Suspended | A Pilot Study to Evaluate PureWick for Nocturia NCT05090722 | Northwell Health | N/A |
| Completed | Abdominal Muscle Exercises on Nocturia and Sleep Quality in Women With Type 2 Diabetes NCT05222477 | Cairo University | N/A |
| Completed | Effects of Transcutaneous Tibial Nerve Stimulation for Overactive Bladder Symptoms in Adults NCT05464589 | Dow University of Health Sciences | N/A |
| Completed | Validation of Capillary Serum Sodium Levels NCT05414279 | University Hospital, Ghent | N/A |
| Completed | Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Scle NCT04528784 | University of Limerick | N/A |
| Unknown | NOGO for an Overactive Bladder NCT04357223 | SagaNatura | Phase 2 |
| Completed | Discovering the Effect of Venous Insufficiency on Nocturia NCT04266496 | University Hospital, Ghent | N/A |
| Withdrawn | Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy NCT02961114 | Robert W. Alexander, MD, FICS | Phase 1 / Phase 2 |
| Recruiting | Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A NCT04305743 | University of South Florida | Phase 4 |
| Completed | Food and Salt Handling in Diuresis NCT04526340 | University Hospital, Ghent | N/A |
| Completed | Discovering the Effect of Venous Insufficiency on Nocturia (DEVINe) NCT03928197 | University Hospital, Ghent | N/A |
| Completed | Impact of Behavioral Treatment of Insomnia on Nighttime Urine Production NCT03883724 | University of Pittsburgh | N/A |
| Completed | Enhancing Behavioral Treatment for Women With Pelvic Floor Disorders NCT03623880 | Northwestern University | N/A |
| Recruiting | Effect of Hormonal Replacement Therapy on Nocturia in Postmenopausal Women NCT04433897 | University Hospital, Ghent | — |
| Withdrawn | Innovative Minimally Invasive Options in Treatment of Urinary Problems Related to Prostate Enlargement (BPH) i NCT03043222 | St. Louis University | N/A |
| Completed | Effectiveness of Bryophyllum in Nocturia-Therapy NCT04480658 | University of Zurich | N/A |
| Completed | A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria i NCT03201419 | Ferring Pharmaceuticals | Phase 2 |
| Completed | Trial Investigating the Long Term Safety and Tolerability of Desmopressin Orally Disintegrating Tablets (ODT) NCT03051009 | Ferring Pharmaceuticals | Phase 3 |
| Completed | Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese M NCT02904759 | Ferring Pharmaceuticals | Phase 3 |
| Completed | Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese F NCT02905682 | Ferring Pharmaceuticals | Phase 3 |
| Completed | Investigation of the Effect of the Female Urinary Microbiome on Incontinence NCT02835846 | Loyola University | Phase 4 |
| Completed | Bioavailability of [14C]-SK-1404 ADME & IV Microtracer Study NCT02878096 | Sanwa Kagaku Kenkyusho Co., Ltd. | Phase 1 |
| Completed | Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH) NCT02637960 | Vantia Ltd | Phase 2 / Phase 3 |
| Completed | Paxerol™ for Treatment of Nocturia - A Phase II Placebo-Controlled Trial NCT02646826 | Wellesley Pharmaceuticals, LLC | Phase 2 |
| Terminated | Study of Minirin Melt® in Adult Patients With Nocturia NCT03089073 | Ferring Pharmaceuticals | — |
| Terminated | Comparison Between Desmopressin and Fesoterodine for Treatment of Night Time Voiding in Women Aged 65 and Olde NCT02262936 | Mount Sinai Hospital, Canada | Phase 2 / Phase 3 |
| Completed | Hormonal Influences on Diuresis NCT04891926 | University Hospital, Ghent | N/A |
| Completed | Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon NCT02440841 | Vantia Ltd | Phase 1 |
| Completed | Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS) NCT02410135 | Southern Illinois University | — |
| Unknown | Melatonin for Nocturia in Parkinson's Disease NCT02359448 | University College, London | Phase 2 |
| Completed | Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia NCT02106182 | JW Pharmaceutical | Phase 4 |
| Withdrawn | Severe Pelvic Organ Prolapse and Post-Obstructive Diuresis (SOPPO) Pilot Study NCT02060331 | Loyola University | — |
| Completed | Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4 NCT01900704 | Serenity Pharmaceuticals, Inc. | Phase 3 |
| Completed | The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence NCT02396160 | The University of Queensland | N/A |
| Terminated | Daytime Impact Sleep Study NCT01779466 | Ferring Pharmaceuticals | Phase 2 |
| Completed | Spanish (Spain) Validation of a Specific Symptomatic Questionnaire for Patients With Nocturia NCT01816724 | Corporacion Parc Tauli | — |
| Completed | Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adul NCT01694498 | Ferring Pharmaceuticals | Phase 2 |
| Completed | Behavioral Therapy to Treat Urinary Symptoms in Parkinson Disease NCT01520948 | Atlanta VA Medical Center | Phase 3 |
| Completed | Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adul NCT01684800 | Ferring Pharmaceuticals | Phase 2 |
| Completed | Dose Range Finding Study of Fedovapagon in Men With Nocturia NCT01656239 | Vantia Ltd | Phase 2 |
| Completed | The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion NCT02068560 | University of Aarhus | N/A |
| Completed | The Effect of Combined Systematized Behavioural Modification Education Program (SyBeMeP) With DDAVP in Patient NCT01576900 | Seoul National University Hospital | — |
| Completed | Desmopressin Melt Therapy in Nocturnal Polyuria Patients: Pharmacodynamic Study NCT01439997 | University Hospital, Ghent | Phase 4 |
| Terminated | Clinical Trial of Desmopressin on Nocturia in Obstructive Sleep Apnoea Patients NCT01530451 | Chinese University of Hong Kong | Phase 3 |
| Completed | Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary NCT01552343 | Ferring Pharmaceuticals | Phase 3 |
| Completed | A Study of Minirin Melt in 24 Months Treatment in Patients With Nocturia NCT01552395 | Ferring Pharmaceuticals | — |
| Completed | Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia NCT01357356 | Serenity Pharmaceuticals, Inc. | Phase 2 / Phase 3 |
| Completed | Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia NCT02151253 | Duke University | Phase 2 / Phase 3 |
| Completed | Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH) NCT01330927 | Vantia Ltd | Phase 1 |
| Completed | Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of N NCT01262456 | Ferring Pharmaceuticals | Phase 3 |
| Completed | Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Noctur NCT01223937 | Ferring Pharmaceuticals | Phase 3 |
| Completed | Efficacy and Safety of Gabapentin in Treating Overactive Bladder NCT01486706 | Michael E. Chua | Phase 2 / Phase 3 |
| Completed | Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo NCT01184859 | Ferring Pharmaceuticals | Phase 2 |
| Completed | VA106483 Dose Response in Females NCT01171391 | Vantia Ltd | Phase 1 |
| Completed | Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia NCT01259128 | Serenity Pharmaceuticals, Inc. | Phase 3 |
| Completed | A Study of Minirin Melt in Patients With Nocturia NCT01212224 | Ferring Pharmaceuticals | — |
| Completed | Efficacy Study of VA106483 in Males With Nocturia. NCT01038843 | Vantia Ltd | Phase 2 |
| Withdrawn | Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness NCT01018225 | Cognitive Research Corporation | Phase 4 |
| Completed | Long Term Safety Assessment of SER120 in Patients With Nocturia NCT00981682 | Serenity Pharmaceuticals, Inc. | Phase 3 |
| Completed | Prevalence and Risk Factors Nocturnal Polyuria in Female OAB NCT03810027 | National Taiwan University Hospital | — |
| Completed | VA106483 Dose Response Study in Elderly Males NCT00922740 | Vantia Ltd | Phase 1 |
| Completed | Treatment of Patients With Nocturia NCT00937859 | Serenity Pharmaceuticals, Inc. | Phase 3 |
| Completed | Treatment of Patients With Nocturia (Non-PK Study) NCT00937378 | Serenity Pharmaceuticals, Inc. | Phase 3 |
| Completed | VA106483 and Alpha Blocker Interaction Study in Elderly Males NCT00879216 | Vantia Ltd | Phase 1 |
| Completed | A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia NCT00793819 | Watson Pharmaceuticals | Phase 2 |
| Completed | A Study of Minirin Melt in Patients With Nocturia NCT01222598 | Ferring Pharmaceuticals | — |
| Completed | Efficacy and Safety of VA106483 in Elderly Males NCT00879138 | Vantia Ltd | Phase 1 / Phase 2 |
| Completed | Behavior and Exercise Versus Drug Treatment in Men With Nocturia (BEDTiMe) NCT00824200 | Atlanta VA Medical Center | Phase 4 |
| Completed | Alpha-blocker Plus Diuretic Combination Therapy as Second-line Treatment for Nocturia in Men NCT00700583 | Seoul National University Hospital | N/A |
| Completed | An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopre NCT00615836 | Ferring Pharmaceuticals | Phase 3 |
| Completed | Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia NCT00477490 | Ferring Pharmaceuticals | Phase 3 |
| Unknown | Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLi NCT00826527 | Seattle Urology Research Center | Phase 4 |
| Completed | Desmopressin in the Treatment of Mixed Nocturia With Nocturnal Polyuria and Low Nocturnal Bladder Capacity NCT00902655 | Samsung Medical Center | Phase 4 |